Drugs / Bifidobacterium triple viable capsule
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06710574 | Sep 2022 → Jun 2025 overdue | Parkinson disease, REM sleep behavior disorder, movement disorder | Beijing Friendship Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium triple viable capsule | “Bifidobacterium triple viable capsule (Bifico Capsule, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., LTD.) 420mg, two times a day, 4 capsules each time” NCT06710574 ↗ |
| Known as | Bifico Capsule | “Bifidobacterium triple viable capsule (Bifico Capsule, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., LTD.) 420mg, two times a day, 4 capsules each time” NCT06710574 ↗ |